Hormone Receptor Positive Breast Carcinoma Clinical Trials

39 clinical trials for Hormone Receptor Positive Breast Carcinoma across international registries, including 17 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• Tai Chi for Reducing Aromatase Inhibitor-Induced Arthralgia — RECRUITING · NA
• Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer — RECRUITING · PHASE3
• Neoadjuvant Breast Cancer Time Restricted Eating — RECRUITING · PHASE2
• 5-strain Probiotic Formulation in HR-positive Breast Cancer Receiving Aromatase Inhibitor to Prevent Bone Loss — RECRUITING · PHASE2
• BGB-43395 Alone or as Part of Combination Therapies in Participants With Breast Cancer and Other Advanced Solid Tumors — RECRUITING · PHASE1
• Safety and Efficacy of T-DXd vs. CDK4/6i-based ET as First-line Therapy of HR-positive and HER2-low/Ultralow Advanced Breast Cancer Patients Classified as Non-luminal Subtype — RECRUITING · PHASE2
• Letrozole With and Without Simvastatin for the Treatment of Stage I-III Hormone Receptor Positive, HER2 Negative Breast Cancer — RECRUITING · PHASE1
• Mobile Health for Adherence in Breast Cancer Patients — RECRUITING · NA
• ARX788 for Treating Patients With HER2-low Locally Advanced Unresectable or Metastatic Breast Cancer — RECRUITING · PHASE2
• AVA6103 in Subjects With Locally Advanced or Metastatic Selected Solid Tumors — RECRUITING · PHASE1
• DiviTum®TKa: A Biomarker Assay for Efficacy in HR+ Breast Cancer Patients — RECRUITING
• Abemaciclib and Endocrine Therapy in Older Patients With Breast Cancer. — RECRUITING · PHASE2
• A Study of Revaree Plus in People With Breast Cancer — RECRUITING · PHASE4
• Acutherapy to Prevent Aromatase Inhibitor-Associated Arthralgias in Non-Hispanic Black Postmenopausal Women With Early-Stage Breast Cancer — RECRUITING · NA
• The Sleep After Breast Cancer (ABC) Study - Examining Sleep Changes and Biomarkers Among Breast Cancer Patients — RECRUITING
• Trastuzumab Deruxtecan Alone or in Combination With Anastrozole for the Treatment of Early Stage HER2 Low, Hormone Receptor Positive Breast Cancer — RECRUITING · PHASE2
• Predicting clinicAL outcoMes During First-line CDK4/6 Inhibitors Plus Endocrine Therapy in Patients With Advanced Hormone REceptor-poSitive HER2-negative Breast Cancer: the Retrospective-prospective Multicenter Italian PALMARES-2 Study — RECRUITING
• Using FDG-PET/CT to Assess Response of Bone-Dominant Metastatic Breast Cancer, FEATURE Study — ACTIVE_NOT_RECRUITING · PHASE2
• BRE-06: Study to Increase Tolerance to Aromatase Inhibitors for Patients With Early-Stage Hormone Receptor Positive Breast Cancer Who Developed Hypoactive Sexual Desire Disorder — NOT_YET_RECRUITING · PHASE1
• National Cancer Institute "Cancer Moonshot Biobank" — ACTIVE_NOT_RECRUITING
• A Dose Escalation/Expansion Study of Oral OP-1250 in Subjects With Advanced and/or Metastatic HR+, HER2- Breast Cancer — COMPLETED · PHASE1
• A Feasibility Trial of a Web Based App Intervention in Hormone Positive Breast Cancer Patients to Improve Adherence to Endocrine Therapy — TERMINATED · NA
• Monitoring Symptoms to Help Young Women Take Hormone Therapy for Stage I-III Breast Cancer, ASPEN Study — ACTIVE_NOT_RECRUITING · NA
• Alpelisib (BYL719) in Combination With Continued Endocrine Therapy Following Progression on Endocrine Therapy in Hormone Receptor Positive, HER2 Negative, PIK3CA Mutant Metastatic Breast Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Breast Cancer Survivors Who Experience Aromatase Inhibitor Associated Musculoskeletal Symptoms (AIMSS) — COMPLETED
• Study of the Monoclonal Antibody IMT-009 in Patients With Advanced Solid Tumors or Lymphomas — ACTIVE_NOT_RECRUITING · PHASE1
• Additional Support Program Via Text Messaging and Telephone-Based Counseling for Breast Cancer Patients Receiving Hormonal Therapy — ACTIVE_NOT_RECRUITING · PHASE3
• Docetaxel, Carboplatin, Trastuzumab, and Pertuzumab With or Without Estrogen Deprivation in Treating Patients With Hormone Receptor-Positive, HER2-Positive Operable or Locally Advanced Breast Cancer — COMPLETED · PHASE3
• Retrospective Study of 2nd-line Therapies After CDK4/6i + Hormonal Therapy in HR+/HER2- Advanced Breast Cancer — COMPLETED
• A Study of XL092 as Single-Agent and Combination Therapy in Subjects With Solid Tumors — ACTIVE_NOT_RECRUITING · PHASE1
• A Multi-Center, Open-Label Study of Fruquintinib in Solid Tumors and Colorectal, and Breast Cancers — COMPLETED · PHASE1
• Study of XL102 as Single-Agent and Combination Therapy in Subjects With Solid Tumors (QUARTZ-101) — TERMINATED · PHASE1
• Oral SM-88 in Patients With Metastatic HR+/HER2- Breast Cancer — TERMINATED · PHASE2
• Neo-Adjuvant Abemaciclib With Fulvestrant in Patients With ER/PR +HER Negative Breast Cancer — TERMINATED · PHASE2
• CLEAR-B: Cancer Landscape - Early Adjuvant Retrospective Registry - Breast Cancer — OTHER
• Monitoring luminAl Breast Cancer Through the Evaluation of Mutational and epiGeNEtic alteraTIons of Circulating ESR1 DNA — OTHER · NA
• Elacestrant in Preoperative Setting, a Window of Opportunity Study — COMPLETED · PHASE1
• Effects of Ribociclib and Palbociclib on Tumor and Blood Characteristics in Patients With Metastatic Breast Cancer — WITHDRAWN · NA
• Abexinostat, Palbociclib, and Fulvestrant for the Treatment of Breast or Gynecologic Cancer — WITHDRAWN · PHASE1

Refine this search